VISIBILITY髂动脉研究:9个月主要与队列结局
VISIBILITY髂动脉研究在美欧17个中心纳入75例Rutherford 2-4级缺血、动脉粥样硬化病变≤10 cm的患者,评估Visi-Pro球囊扩张支架治疗髂总或髂外动脉狭窄、再狭窄或闭塞病变的安全性与有效性。9个月主要不良事件发生率为4.0%,一期通畅率和免于临床驱动的靶血管血运重建率均为95.8%。
要点
- 9个月主要不良事件率4.0%,一期通畅率与免于CD-TVR率均为95.8%。
- 踝肱指数由基线0.67±0.14升至30天0.94±0.14、9个月0.96±0.16(均p<0.001)。
- 各分析队列(含性别)间结局未见差异,器械全部成功释放。
核心结论
- Visi-Pro支架治疗髂总与髂外动脉粥样硬化病变在9个月时显示安全有效,各治疗队列结果一致。
研究设计与样本
- 前瞻性多中心研究,2011至2012年在美国和欧洲17个中心纳入75例患者(平均年龄64.2±8.9岁,46例男性)。
- 入选者为Rutherford 2-4级缺血且动脉粥样硬化病变长度≤10 cm,接受髂总或髂外动脉支架置入。
- 主要结局为术后9个月主要不良事件率,复合围手术期死亡、院内心肌梗死、临床驱动的靶病变血运重建与治疗肢体截肢。
- 次要结局包括30天主要不良事件率、9个月一期通畅率、30天与9个月踝肱指数及步行障碍问卷变化、器械成功率、30天与9个月临床驱动的靶血管血运重建。
- 按性别、支架位置、钙化程度与病变分级进行队列分析。
主要发现
- 平均治疗病变长度29.3±13.9 mm,所有器械均成功释放。
- 9个月时75例受试者中3例(4.0%)发生主要不良事件。
- 9个月一期通畅率与免于临床驱动的靶血管血运重建率均为95.8%。
- 踝肱指数从基线0.67±0.14改善至30天0.94±0.14和9个月0.96±0.16(两者p<0.001)。
关键数值与推荐
- 主要不良事件定义:围手术期死亡、院内心肌梗死、临床驱动的靶病变血运重建与治疗肢体截肢的复合终点。
- 9个月主要不良事件率为4.0%(3/75)。
- 9个月一期通畅率与免于临床驱动的靶血管血运重建率均为95.8%。
- 踝肱指数基线0.67±0.14,30天0.94±0.14,9个月0.96±0.16,两者p<0.001。
临床怎么用
- 对于Rutherford 2-4级缺血、髂总或髂外动脉动脉粥样硬化病变≤10 cm者,可考虑使用Visi-Pro球囊扩张支架。
- 术后9个月应关注主要不良事件、一期通畅率及踝肱指数与步行能力的改善。
- 中重度钙化、不同支架位置与性别队列的9个月结局未见差异,可作个体化决策参考。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the safety and effectiveness of primary stenting of the common (CIA) or external iliac artery (EIA) using the Visi-Pro Balloon-Expandable Peripheral Stent System for treatment of stenotic, restenotic, or occluded lesions. METHODS: Between 2011 and 2012, 75 patients (mean age 64.2±8.9 years; 46 men) with Rutherford category 2-4 ischemia and atherosclerotic lesions ≤10 cm in length underwent iliac artery stenting at 17 centers in the United States and Europe. The primary outcome of the study was the major adverse event (MAE) rate at 9 months postprocedure [composite of periprocedural death, in-hospital myocardial infarction, clinically driven target lesion revascularization (CD-TLR), and amputation of the treated limb]. Secondary outcomes included 30-day MAE rate, 9-month primary patency, changes in ankle-brachial index (ABI) and the Walking Impairment Questionnaire at 30 days and 9 months postprocedure, device success, and clinically driven target vessel revascularization (CD-TVR) at 30 days and 9 months. Outcomes in specific patient cohorts (ie, gender, stent location, calcification severity, and lesion grade) were analyzed. RESULTS: Eighty-one stents were implanted in 61 CIA and 15 EIA lesions (41 with moderate/severe calcification). The mean lesion treated length was 29.3±13.9 mm. All devices were successfully deployed. MAE occurred in 3 (4.0%) of 75 subjects at 9 months. Primary patency and freedom from CD-TVR at 9 months were both 95.8%. ABI improved from 0.67±0.14 at baseline to 0.94±0.14 and 0.96±0.16 at 30 days and 9-month follow-up, respectively (p<0.001 for both). There were no differences with respect to any of the analyzed patient characteristics, including gender. CONCLUSION: Nine-month results of the VISIBILITY Iliac stent study ( ClinicalTrials.gov identifier NCT01402700) demonstrated safety and effectiveness for the treatment of atherosclerotic CIA and EIA lesions with the Visi-Pro stent across all treated cohorts.
引用
- Rundback JH, Peeters P, George JC, et al. Results From the VISIBILITY Iliac Study: Primary and Cohort Outcomes at 9 Months. J Endovasc Ther. 2017. PMID: 28351204. doi:10.1177/1526602817692960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。